Waldencast (WALD) announced that the U.S. FDA has approved Obagi saypha MagIQ injectable hyaluronic acid gel, the first product in the Obagi saypha collection under the Obagi Medical brand. This approval marks Waldencast’s entry into the U.S. HA dermal filler market through Obagi Medical and reinforces the company’s ambition to become a multi-product innovator in aesthetics, doubling Obagi Medical’s total addressable market to approximately $4.2B by 2029.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WALD:
- Waldencast Reports Strategic Growth and New Acquisitions
- Waldencast’s Strategic Positioning and Growth Potential: A Buy Rating Amidst Strategic Review and Financial Restructuring
- Waldencast price target lowered to $3 from $4 at Telsey Advisory
- Waldencast price target lowered to $2 from $2.40 at TD Cowen
- Waldencast Reports Strong H1 2025 Growth and Strategic Initiatives